secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001213900-25-050756
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Oruka Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- Elected Carl Dambkowski (26,047,914 for) and Peter Harwin (25,935,823 for) as Class I directors.
- Ratified PricewaterhouseCoopers as independent auditor for FY 2025 (26,781,030 for, 1,848 against).
- Non-binding advisory vote approved named executive officer compensation (25,824,834 for, 88,740 against).
- Non-binding vote favored annual frequency for future say-on-pay; board adopted annual frequency.
- All proposals passed; broker non-votes of 732,854 on director and compensation proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390025050756/0001213900-25-050756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390025050756/ea0244429-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer